Business | Thomson Reuters | Friday October 16, 2015
Leaders of India's $15 billion pharmaceuticals industry, a major supplier of affordable generics to the world, have joined public health activists in criticising a new US-led trade deal they say will delay the arrival of new cheap drugs.
www.ndtv.com/business